THE LONG-TERM EFFECTS OF THE RODENTICIDE, BRODIFACOUM, ON BLOOD-COAGULATION AND VITAMIN-K METABOLISM IN RATS

被引:39
作者
MOSTERD, JJ [1 ]
THIJSSEN, HHW [1 ]
机构
[1] STATE UNIV LIMBURG,DEPT PHARMACOL,6200 MD MAASTRICHT,NETHERLANDS
关键词
ANTICOAGULATION; BINDING SITE; BRODIFACOUM; VITAMIN-K CYCLE; VITAMIN-K EPOXIDE REDUCTASE; WARFARIN;
D O I
10.1111/j.1476-5381.1991.tb12463.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 The long-term (30 days) effects of a single dose of brodifacoum (0.2 mg kg-1, orally) on blood clotting activity and on liver parameters of the vitamin K cycle were investigated in rats. Maximal effect on blood clotting activity was seen on day one. On day seven blood clotting activity had returned to normal. 2 Liver microsomal vitamin KO reductase activity was maximally suppressed (10% of control activity) on day one, steadily recovered to about 40% on day 15 to remain at that level. The same time course was seen for the number of microsomal warfarin binding sites. 3 The persistent inhibition of the vitamin K cycle was also verified in vivo; following vitamin K administration (10 mg kg-1, i.v.) on day 30, the brodifacoum-treated rats accumulated vitamin KO in the liver. 4 Although clotting factor synthesis was normal, brodifacoum-treated rats were highly sensitive to warfarin. 5 Brodifacoum rapidly accumulated in the liver until the saturation of the microsomal binding site. Brodifacoum binding to the target prevented its elimination from the liver; liver content on day 30 was not different from day 7. 6 The results show (1) an over capacity for the hepatocellular vitamin K cycle, (2) a dissociation of the vitamin K epoxidation and the vitamin K-dependent carboxylation, (3) the 'superwarfarin' rodenticides to be extremely persistent due to their binding to the target.
引用
收藏
页码:531 / 535
页数:5
相关论文
共 26 条
[1]   DISPOSITIONAL AND PHARMACODYNAMIC CHARACTERISTICS OF BRODIFACOUM IN WARFARIN-SENSITIVE RATS [J].
BACHMANN, KA ;
SULLIVAN, TJ .
PHARMACOLOGY, 1983, 27 (05) :281-288
[2]  
BECHTOLD H, 1983, LANCET, V1, P596
[3]  
BOROWSKI M, 1985, J BIOL CHEM, V260, P9258
[4]  
BOROWSKI M, 1986, J BIOL CHEM, V261, P1624
[5]  
BRECKENRIDGE AM, 1985, BRIT J PHARMACOL, V84, P81
[6]   VITAMIN-K1 METABOLISM IN RELATION TO PHARMACODYNAMIC RESPONSE IN ANTICOAGULATED PATIENTS [J].
CHOONARA, IA ;
SCOTT, AK ;
HAYNES, BP ;
CHOLERTON, S ;
BRECKENRIDGE, AM ;
PARK, BK .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 20 (06) :643-648
[7]  
CHOONARA IA, 1988, BRIT J CLIN PHARMACO, V25, P1
[8]  
DRUMMOND D, 1966, NEW SCIENTIST, V30, P771
[9]   WARFARIN INHIBITION OF VITAMIN-K 2,3-EPOXIDE REDUCTASE IN RAT-LIVER MICROSOMES [J].
FASCO, MJ ;
PRINCIPE, LM ;
WALSH, WA ;
FRIEDMAN, PA .
BIOCHEMISTRY, 1983, 22 (24) :5655-5660
[10]   HERITABLE RESISTANCE TO WARFARIN IN RATS [J].
GREAVES, JH ;
AYRES, P .
NATURE, 1967, 215 (5103) :877-&